Global Cephalosporin Drugs Market Expected To Reach XX Million By 2025

2018-05-14 11:39:48

Cephalosporin Drugs Market Overview
According to a new report published by Reports Monitor titled, “Cephalosporin Drugs Market by Type, Generation, Route of Administration, and Application: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the cephalosporin drugs market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. 

In recent past few years’ organisms have gained resistance towards various drugs which reduces or diminishes impact of the medicine. This brings out need for next generation drug to be designed in order to treat the infection or disease. The cephalosporins are family of drugs which are bactericidal beta lactam antibiotics.  Cephalosporins bind to penicillin binding proteins on bacteria and inhibit the synthesis of the bacterial cell wall, resulting in cell lysis specifically in rapidly growing organisms. Until now five generation of cephalosporin have been introduced with different antibacterial activity. Earlier cephalosporin was active against gram positive bacteria, nonetheless progressive generation of the drug is showing activity against gram negative bacteria with comparatively less action towards gram positive once. On the other hand, fourth generation of cephalosporin possess broad range of action. 

More Insightful Information | Request a Sample Copy @

Upsurge in number of people distressing from infectious diseases globally and rising demand for effective drugs for treatment purpose drives the demand for cephalosporin drug market. Increased expenditure on research and development for newer generations of drugs, favourable administrative guidelines and availability of funding further boosts the growth of the market. However, conflicting adverse effects pertaining to cephalosporin including vaginal & oral candidiasis, nausea, headache, vomiting, diarrhoea and several others aspects might restrict the growth of the market. Besides, along with each upgrading generation, resistance exhibited by the organism is decreasing the effect of cephalosporin as broad spectrum antibiotic hindering the market growth. Large population base of China followed by India supports the growth of Asian-Pacific countries. India is one of the most propitious markets for cephalosporin with total population of more than 1.2 billion followed by China. Other aspects imputing to the growth of the market are increasing per capta income, presence of unmet medical demand and increased awareness among people.

The global cephalosporin market is differentiated based on type, generation, route of administration, application and geography. In terms of type the market is segmented into generic cephalosporin drug and branded cephalosporin drug.  On the basis of generation market is separated into first, second, third, fourth and fifth generation. Depending upon route of administration the market is categorized into oral cephalosporin drug and cephalosporin injections. In terms of application market is differentiated into sexually transmitted infection, urinary tract infection, ear infection, Skin infection, respiratory infection and many others. 

Competitive Landscape
The major players performing in the market are Allergan, Astellas, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Pfizer, Sandoz, Lupin Pharmaceuticals. Other Prominent Vendors include Eli Lilly, Biocon, Johnson & Johnson, Sanofi and Takeda Pharmaceuticals.
Since investment cost of R&D is and cost of further manufacturing process is increasing many small scale companies are making collaboration and partnership with larger firms. For Instance, Shionogi & Co. Ltd recently collaborated with F. Hoffmann-La Roche Ltd specifically for a development of siderophore cephalosporin

About Garner Insights:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases